Data Integrity Issues Lead to Warning Letter for Czech Facility

International Pharmaceutical Regulatory Monitor
A A
Interpharm Praha has received an FDA warning letter that cites data integrity issues at a facility in the Czech Republic.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor